News - Appointments

The Belgian immunotherapy company iTeos Therapeutics SA has appointed Matthew Call as chief operating officer to guide business development as its cancer drugs progress through the clinic. iTeos’ lead programme is an adenosine A2A receptor antagonist in Phase 1 for advanced cancer.

Circassia Pharmaceuticals Plc has appointed the former Pfizer Inc executive Jonathan Emms to the newly created role of chief operating officer to lead the commercialisation of the company’s respiratory products.

Karus Therapeutics Ltd, a British biotech developing small molecules for cancer, has appointed Hilary McElwaine-Johnn to the position of chief medical officer. Dr McElwaine-Johnn is a physician with more than 25 years of experience in drug development.

Domain Therapeutics SA of Strasbourg, France has appointed Xavier Leroy to the position of chief technology officer (CTO) to drive development of the company’s G protein-coupled receptor (GPCR) drug discovery platform.

PhoreMost Ltd, a 2015 spin-out from Cambridge University with technology for identifying new drug targets, has appointed Lorenz Mayr to its board as a non-executive director.

Patrick Tricoli has become global head of business development at Nanobiotix SA following a corporate reorganisation which also saw Edwina Baskin-Bey become chief medical officer and Elsa Borghi head of drug discovery.

UK entrepreneur John Burt has been named chief executive of Medherant Ltd, a company with a clinical-stage transdermal patch for the treatment of pain.

Matthew Hill has joined UK-based Evonetix Ltd as head of mechanical engineering to help guide development of the company’s silicon chip technology for the synthesis of DNA. He was previously business manager at Cambridge Consultants which is an investor in Evonetix.

UK-based TrakCel Ltd has expanded its management team in the US with the appointment of Maryellen Papelian as senior director for customer delivery. TrakCel provides software for organising IT and other services for the cell and gene therapy industry.

Giorgio Calderari, chief operating officer and general manager of the Helsinn Group, has joined the board of directors of Helsinn Holding SA following the departure of Carlo Donati who stepped down after eight years of service.